Abstract
ObjectiveWe previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. We now aim to further delineate the immunogenomic classification of HCC to incorporate features that explain responses/resistance to immunotherapy.DesignWe performed RNA and whole-exome sequencing, T-cell receptor (TCR)-sequencing, multiplex immunofluorescence and immunohistochemistry in a novel cohort of 240 HCC patients and validated our results in other cohorts comprising 660 patients.ResultsOur integrative analysis led to define: (1) the inflamed class of HCC (37%), which includes the previously reported immune subclass (22%) and a new immune-like subclass (15%) with high interferon signalling, cytolytic activity, expression of immune-effector cytokines and a more diverse T-cell repertoire. A 20-gene signature was able to capture ~90% of these tumours and is associated with response to immunotherapy. Proteins identified in liquid biopsies recapitulated the inflamed class with an area under the ROC curve (AUC) of 0.91; (2) The intermediate class, enriched inTP53mutations (49% vs 29%, p=0.035), and chromosomal losses involving immune-related genes and; (3) the excluded class, enriched inCTNNB1mutations (93% vs 27%, p<0.001) andPTK2overexpression due to gene amplification and promoter hypomethylation.CTNNB1mutations outside the excluded class led to weak activation of the Wnt-βcatenin pathway or occurred in HCCs dominated by high interferon signalling and type I antigen presenting genes.ConclusionWe have characterised the immunogenomic contexture of HCC and defined inflamed and non-inflamed tumours. Two distinctCTNNB1patterns associated with a differential role in immune evasion are described. These features may help predict immune response in HCC.
Funder
Dr. Franklin M. Klion Young Scientist Research Award
Generalitat de Catalunya
National Cancer Institute
PhD Scientist Innovative Research Award
Instituto de Salud Carlos III
Samuel Waxman Cancer Research Foundation
Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears
Cancer Research UK
Associazione Italiana per la Ricerca sul Cancro
U.S. Department of Defense
Tisch Cancer Institute
Horizon 2020 Framework Programme
Deutsche Forschungsgemeinschaft
Fundación Científica Asociación Española Contra el Cáncer
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
Agència de Gestió d’Ajuts Universitaris i de Recerca
Bristol-Myers Squibb
National Institute of Diabetes and Digestive and Kidney Diseases
Reference47 articles.
1. Hepatocellular carcinoma;Llovet;Nat Rev Dis Primers,2021
2. Hepatocellular carcinoma;Villanueva;N Engl J Med Overseas Ed,2019
3. Immunotherapies for hepatocellular carcinoma;Llovet;Nat Rev Clin Oncol,2021
4. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med Overseas Ed,2020
5. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma;Cheng;J Hepatol,2021
Cited by
129 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献